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The aim of this study was to measure the activity of 2',5'-oligoadenylate synthetase (2',5'AS)
which is mainly induced by interferon (IFN)-α and -β in patients with major depression
and evaluate its relationship to the disease.  2',5'AS activity of 23 patients (male = 11,
female = 12) with major depression and of 29 normal control subjects (male = 15, female
= 14) was measured in peripheral blood mononuclear cells (PBMCs) by radioassay.  The
mean 2',5'AS activity in the PBMCs of the patients and that of the control subjects were
1.10 ± 0.69% and 0.72 ± 0.51%, respectively.  The activity in the patients was statistically
higher than that of the control subjects (P = 0.03).  These results imply some abnormality
in the IFN-2',5'AS system of patients with major depression.
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Major depressive disorder which is called major
depression commonly is an agnogenic psychiatric
illness whose main symptoms are disturbed drive
and mood.  The patient of major depression often
shows loss of appetite, sleep disturbance, depressed
mood, a feeling of sadness, helplessness, worthless-
ness and so on.  Major depression and chronic fa-
tigue syndrome (CFS) have some similar symp-
toms.  However, it has been controversial whether
they have a common pathological mechanism or not
(Krusei et al., 1989; Lane et al., 1991; Terman et al.,
1998).  It has been reported that 2',5'-oligoadenylate
synthetase (2',5'AS) activity within peripheral
blood mononuclear cells (PBMCs) was elevated in
patients with CFS (Suhadolnik et al., 1994; Vojdani
et al., 1998; Ikuta et al., 2003).  2',5'AS is known as
an interferon (IFN)-induced antiviral and anti-
proliferative gene product.  2',5'AS is mainly induc-
ed by IFN-α and -β, and 2',5'AS activity levels are
thought to reflect the in vivo state of the IFN system
(Sokawa et al., 1980; Shindo et al.,1989).
It is also known that IFN therapy for patients
with type B and C hepatitis and malignant tumors
induces 2',5'AS and sometimes causes serious fa-
tigue and a depressive state.  Because of these side
effects, patients are treated with antidepressants, or
IFN therapy is sometimes discontinued (Borden et
al., 1998; Licinio et al., 1998; Valentine et al., 1998;
Musselman et al., 2001).  The question is whether
or not and how much endogenous IFNs are involv-
ed in major depression.  But it is difficult to evalu-
ate IFN production, because cytokines including
IFN are released and consumed locally at the site
where the immune reaction occurs and they are
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seldom detectable in peripheral blood (De Groote et
al., 1992).  2',5'AS activity has been measured alter-
natively to IFN-α and -β activity (Sokawa et al.,
1980; Schattner et al., 1981; Uno et al., 1998).  IFN-
α and -β in sera of patients with major depression
have never been evaluated in a proper manner.  The
aim of this study is to measure the activity of
2',5'AS in PBMCs of patients with major depres-
sion and evaluate its relationship to the disease.
This is the 1st report regarding 2',5'AS activity in
patients with major depression, as far as we know.
Materials and Methods
Subjects
This study was permitted by the Medical Ethics
Committee at the Tottori University Faculty of
Medicine.  Informed consent was obtained from
every patient and healthy control subject with a
detailed explanation of the purpose and goal of the
study.
Eleven male and 12 female patients (mean
age: 39.4 ± 10.9 years ranging from 20 to 53 years)
with major depression and 15 male and 14 female
healthy subjects (mean age: 37.5 ± 11.5 years rang-
ing from 20 to 59 years) as controls participated in
this study.  There was no significant difference be-
tween the patient and the healthy control groups
concerning age and sex ratio (Table 1).  The clinical
diagnosis for major depressive disorder was based
on Diagnostic and statistical
manual of mental disorders,
4th ed. (DSM-IV) criteria
(American Psychiatric As-
sociation, 1994).  Exclusion




ease, CFS or other acute
physical diseases for both
groups.  Subjects were ex-
cluded if they fulfilled any
additional axis I or axis II
DSM-IV diagnosis for the
patients and any axis I or axis II DSM-IV diagnosis
for control subjects, respectively.  These illnesses
were ruled out by clinical interview, physical exam-
ination and comprehensive laboratory work.  For
the assessment of depressive severity, psychopath-
ology was quantified by the Hamilton depression
rating scale (HAMD) 21-item version at the time of
blood sampling (Hamilton, 1960).  The mean
HAMD score of the patients was 20.8 ± 5.9 ranging
from 15 to 36.  Most of them were on antidepres-
sants such as clomipramine, maprotiline and fluvo-
xamine, while some were on benzodiazepines such
as diazepam and flunitrazepam.  The mean daily
doses of antidepressants and benzodiazepins in
each patient were 79.8 ± 86.0 mg (imipramine
equivalents; range: 0–265 mg) and 15.8 ± 19.3 mg
(diazepam equivalents; range: 0–81.5 mg), respec-
tively.  Inagaki’s conversion tables for antidepres-
sants and benzodiazepines were used (Inagaki et al.,
1999).  The mean durations of illness and treatment
were 82.0 ± 79.0 months ranging from 1 to 324
months and 38.4 ± 54.0 months ranging from 0.3 to
192 months, respectively (Table 1).
2', 5'AS activity assay
Peripheral blood was collected between 0900 and
1200 from each subject and kept on ice.  PBMCs
were isolated within 30 min by Ficoll-Conray
centrifugation (Boyum, 1968).  The 2',5'AS activity
was measured as previously described (Sokawa et
al., 1980; Ikuta et al., 2003).  For the assay, buffer A
Table 1.  Profiles and 2',5'AS activity of patients with major depression
and control subjects
                                                              Patient          Control subject      Statistics
Age (year) 39.7  ± 10.9 37.5  ± 11.5      NS†
Sex ratio (male/female)      11/12      15/14      NS‡
HAMD 20.8  ±   5.9        ND
Dose of antidepressants (mg) 79.8  ± 86.0         0
Dose of benzodiazepines (mg) 15.8  ± 19.3         0
Duration of illness (month) 82.0  ± 79.0        —
Duration of treatment (month) 38.4  ± 54.0         0
2',5'AS activity (%)   1.10 ±  0.69   0.72 ±  0.51  P < 0.05†
Data are mean ± SD, except the sex ratio.
ND, not determined; NS, no significant difference.
† Student’s t-test was used for statistical analysis.
‡ χ2 test was used for statistical analysis.
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[10 mM HEPES (adjusted to pH 7.5 by 1 M KOH),
3 mM magnesium acetate, 0.3 mM EDTA and 10%
glycerol], buffer B (50 mM KCl in buffer A), buffer
C [0.2 mM phenylmethyl sulfonyl fluoride (PMSF)
and 7 mM 2-mercaptoethanol in buffer B] and
buffer D (400 mM KCl in buffer A) were prepared
and stocked at 4˚C until use.
The procedure of 2',5'AS activity assay was
done at room temperature, if not mentioned other-
wise.  The 106 PBMCs were washed with phosphate
buffered saline and were suspended in 40 µL of
Triton extraction buffer (0.5% Triton X-100, 7 mM
2-mercaptoethanol and 1 mM PMSF in buffer B).
The sample was mixed well by pipetting, and the
cell extract of the sample was obtained by centrifu-
gation at 14,000 rpm for 5 min at 4˚C.  The cell
extract was stored at –80˚C and used for the 2',5'AS
activity assay within 1 week:  20 µL of the cell ex-
tract was added to 25 µL of agarose-polyriboinosinc
acid-polyribocytidylic acid [AG Poly(I) Poly(C)
type 6:  Amersham Pharmacia Biotech, Tokyo,
Japan] and put on ice for 1 h to activate 2',5'AS in
the cell extract.  The AG Poly(I) Poly(C) was equil-
ibrated with buffer C before use.  Then, 1 mL of
buffer C was added to the mixture which contains
2',5'AS with AG Poly(I) Poly(C) and followed by
centrifugation at 5,000 rpm for 1 min.  The washed
beads were incubated at 33˚C for 2 h with 20 µL of
buffer B containing 0.5 mM cold ATP and 0.4 µCi
of 3H-ATP (Moravek Biochemicals, LaBrea, CA).
The sample was suspended in 1 mL of buffer C and
the supernatant was collected by centrifugation at
5,000 rpm for 1 min.  The product [3H-2',5'-oligo-
adenylate (3H-2',5'-A)] was absorbed on 50 µL of
diethylaminoethyl (DEAE) Sepharose CL-6
(Amersham Pharmacia Biotech) pre-equilibrated
with buffer C.  The DEAE Sepharose was washed 5
times with 1 mL of buffer C and then suspended in
500 µL of buffer D to solubilize 3H-2',5'-A.  The
radioactivity of 3H-2',5'-A in each sample was mea-
sured in a scintillator (ACS2: Amersham Pharmacia
Biotech) by a scintillation counter.  The 2',5'AS ac-
tivity was expressed as a percentage of the incorpo-
rated 3H-ATP by the enzyme in each sample.  It
took about 6 h from equilibration of AG Poly(I)
Poly(C) to the measure of radioactivity.  The intra-
and inter-assay coefficients for 2',5'AS activity
were 4.8% and 16.6%, respectively.
Statistical analysis
Statistical differences in age and 2',5'AS activity
between the 2 groups were estimated by Student’s t-
test and that of sex distribution was estimated by the
χ2 test.  Statistical difference in 2',5'AS activity
between all male and female subjects was estimated
by Student’s t-test.  Coefficients of 2',5'AS activi-
ties with ages, HAMD scores, dose of antidepres-
sants, dose of benzodiazepines, duration of illness
and duration of treatment were estimated by
Pearson’s coefficient.  Differences were considered
to be significant when P values were less than 0.05.
Results
2',5'AS activity was assayed in PBMCs of patients
with major depression and healthy control subjects
(Fig. 1).  The mean 2',5'AS activity of ATP incorpo-
ration rate in patients with major depression and
that of the healthy control subjects were 1.10 ±
0.69% and 0.72 ± 0.51%, respectively.  2',5'AS ac-
tivity in the patients was statistically higher than




















Fig. 1.  The activity of 2',5'AS in PBMCs of patients with
major depression and normal control subjects.  Each dot
shows the 2',5'AS activity for each subject.  The mean
2',5'AS activity (± SD) in patients and that of the control
subjects were 1.10 ± 0.69% and 0.72 ± 0.51%, respec-
tively.
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No significant correlation between 2',5'AS
activities in PBMCs and age, HAMD scores, dose
of antidepressants, dose of benzodiazepines, dura-
tion of illness or duration of treatment was observed
in the patients, as well as no significant correlation
between 2',5'AS activities in the PBMCs and ages
in the healthy control subjects.  There was also no
significant sex difference of 2',5'AS activity in the
PBMCs of all subjects.
Discussion
We found that 2',5'AS activity was significantly
elevated in PBMCs of the patients with major
depression to that of the healthy control subjects.
A depressive state is found during IFN therapy
as a side effect.  IFN therapy which induces 2',5'AS
causes not only a central nervous system-depressive
state but also somatic symptoms such as joint pain,
muscle pain, fatigue and so on (Borden et al., 1998).
Major depression is sometimes accompanied by
those somatic symptoms, which are thought to be
one of the aspects of major depression.  The ques-
tion was whether or not and how much endogenous
IFNs are involved in major depression.   IFN-α and
-β in sera of patients with major depression have
never been evaluated in a proper manner.  Our
results imply the involvement of IFN-α and -β in
major depression.
Elevation of 2',5'AS activity in PBMCs of
patients with CFS has been reported (Suhadolnik et
al., 1994; Vojdani et al., 1998; Ikuta et al., 2003).  In
our study, 2',5'AS activity in PBMCs were also
elevated in the patients with major depression.
Even though CFS and major depression are mutual-
ly exclusive by strict diagnostic definition, there are
many reports which indicate clinical overlapping or
some connections between CFS and major depres-
sion (Krusei et al., 1989; Lane et al., 1991; Fukuda
et al., 1994; Terman et al., 1998).
2',5'AS activity especially has been noticeable
with viral infections (Schattner et al., 1981; Buffet-
Janversse et al., 1983; Shindo et al., 1988).  For the
relation between virus and major depression, Borna
disease virus antibody has been reported to be
detectable within sera in patients with major de-
pression (Bode et al., 1993).  Our results may sug-
gest the involvement of viral infections in patients
with major depression.
Elevation of 2',5'AS activity in PBMCs of pa-
tients with major depression may be explained by
another possibility: major depression is usually ac-
companied by decreased natural killer cell func-
tions (Stein et al., 1991), and 2',5'AS might be acti-
vated as the alternative defense mechanism.  The
elevation of 2',5'AS activity in CFS could be a pri-
mary abnormality, because 37 kDa RNase L which
is a truncated form of the native 83 kDa RNaseL is
detected in patients with CFS but not in patients
with major depression nor in healthy controls
(Suhadolnik et al., 1997; De Meirleir et al., 2000;
Demettre et al., 2002).  RNase L is an enzyme which
is activated with the 2',5'AS system to degrade
cellular and viral single strand RNA.  Thus there
seems to be a different mechanism between major
depression and CFS according to the elevation of
2',5'AS activity.
Most of our patients with major depression
had antidepressants and benzodiazepines.  Re-
cently, it has been reported that antidepressants
have a critical effect on the cytokine production of
IFN-γ (Maes et al., 1999; Kubera et al., 2001).  Even
though we observed no significant correlation be-
tween 2',5'AS activity and those drugs in the pa-
tients, the possibility that antidepressants or benzo-
diazepines up-regulate 2',5'AS activity remains.  In
order to study the effects of those drugs on 2',5'AS
activity, 2',5'AS activity in patients with major de-
pression must be assayed before and after treatment
with the drugs.
In conclusion, our study demonstrates the sig-
nificant elevation of 2',5'AS activity in major de-
pression, which implies the involvement of the
IFN-2',5'AS system.  The possible mechanisms of
up-regulation of the enzyme remain to be studied.
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